阿帕他胺药物相互作用的生理药代动力学模型研究(第2部分)
本研究采用生理药代动力学模型预测CYP3A4和CYP2C8抑制剂/诱导剂对阿帕他胺稳态药代动力学及总效力调整的药理活性部分的影响,并模拟单次与重复给药阿帕他胺240 mg与酮康唑、吉非罗齐或利福平联用的药物相互作用。结果表明,与强CYP3A4/CYP2C8抑制剂/诱导剂联用时,阿帕他胺或其药理活性部分的药代动力学预计无重大变化,支持现有建议:联用已知CYP2C8或CYP3A4抑制剂或诱导剂时无需调整剂量。
要点
- 阿帕他胺单次给药后CYP2C8和CYP3A4代谢贡献分别为58%和13%,稳态时为40%和37%。
- 酮康唑使阿帕他胺稳态Cmax、AUC分别增加38%、51%,药理活性部分增加23%、28%。
- 吉非罗齐使阿帕他胺稳态Cmax、AUC分别增加32%、44%,药理活性部分增加19%、23%。
核心结论
- 基于模拟,与强CYP3A4/CYP2C8抑制剂或诱导剂联用时,阿帕他胺或其药理活性部分的药代动力学预计无重大变化。
- 该观察支持现有建议:阿帕他胺与已知CYP2C8或CYP3A4抑制剂或诱导剂联用期间无需调整剂量。
研究设计与样本
- 采用生理药代动力学模型进行预测,模拟单次与重复给药阿帕他胺240 mg与酮康唑、吉非罗齐或利福平联用的药物相互作用。
主要发现
- 单次给药后CYP2C8和CYP3A4对阿帕他胺代谢的贡献估计分别为58%和13%,稳态时分别为40%和37%。
- 酮康唑预测使阿帕他胺稳态Cmax增加38%、AUC增加51%,药理活性部分Cmax增加23%、AUC增加28%。
- 吉非罗齐预测使阿帕他胺稳态Cmax增加32%、AUC增加44%,药理活性部分Cmax增加19%、AUC增加23%。
- 利福平预测使阿帕他胺稳态Cmax降低25%、AUC降低34%,药理活性部分Cmax降低15%、AUC降低19%。
临床怎么用
- 临床联用强CYP3A4/CYP2C8抑制剂或诱导剂时,基于本研究模拟结果无需调整阿帕他胺剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Apalutamide is predominantly metabolized via cytochrome P450 (CYP) 2C8 and CYP3A4, whose contributions change due to autoinduction with repeated dosing. OBJECTIVES: We aimed to predict CYP3A4 and CYP2C8 inhibitor/inducer effects on the steady-state pharmacokinetics of apalutamide and total potency-adjusted pharmacologically active moieties, and simulated drug-drug interaction (DDI) between single-dose and repeated-dose apalutamide coadministered with known inhibitors/inducers. METHODS: We applied physiologically based pharmacokinetic modeling for our predictions, and simulated DDI between single-dose and repeated-dose apalutamide 240 mg coadministered with ketoconazole, gemfibrozil, or rifampicin. RESULTS: The estimated contribution of CYP2C8 and CYP3A4 to apalutamide metabolism is 58% and 13%, respectively, after single dosing, and 40% and 37%, respectively, at steady-state. Apalutamide exposure is predicted to increase with ketoconazole (maximum observed concentration at steady-state [Cmax,ss] 38%, area under the plasma concentration-time curve at steady-state [AUCss] 51% [pharmacologically active moieties, Cmax,ss 23%, AUCss 28%]) and gemfibrozil (Cmax,ss 32%, AUCss 44% [pharmacologically active moieties, Cmax,ss 19%, AUCss 23%]). Rifampicin exposure is predicted to decrease apalutamide (Cmax,ss 25%, AUCss 34% [pharmacologically active moieties, Cmax,ss 15%, AUCss 19%]). CONCLUSIONS: Based on our simulations, no major changes in the pharmacokinetics of apalutamide or pharmacologically active moieties are expected with strong CYP3A4/CYP2C8 inhibitors/inducers. This observation supports the existing recommendations that no dose adjustments are needed during coadministration of apalutamide and the known inhibitors or inducers of CYP2C8 or CYP3A4.
引用
- Van den Bergh A, Snoeys J, De Zwart L, et al. Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model. Clin Pharmacokinet. 2020. PMID: 32338346. doi:10.1007/s40262-020-00881-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。